Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1276270.RA6fshZS7muOi4P-MIthWlNkR1oIZuGcpx5xekfpGCE8U130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1276270.RA6fshZS7muOi4P-MIthWlNkR1oIZuGcpx5xekfpGCE8U130_assertion type Assertion NP1276270.RA6fshZS7muOi4P-MIthWlNkR1oIZuGcpx5xekfpGCE8U130_head.
- NP1276270.RA6fshZS7muOi4P-MIthWlNkR1oIZuGcpx5xekfpGCE8U130_assertion description "[This single-arm phase II study enrolled patients with stage I to IIIA (T ? 1 cm) estrogen receptor-negative (? 5%), progesterone receptor-negative (? 5%), and human epidermal growth factor receptor 2-negative or BRCA1/2 mutation-associated breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1276270.RA6fshZS7muOi4P-MIthWlNkR1oIZuGcpx5xekfpGCE8U130_provenance.
- NP1276270.RA6fshZS7muOi4P-MIthWlNkR1oIZuGcpx5xekfpGCE8U130_assertion evidence source_evidence_literature NP1276270.RA6fshZS7muOi4P-MIthWlNkR1oIZuGcpx5xekfpGCE8U130_provenance.
- NP1276270.RA6fshZS7muOi4P-MIthWlNkR1oIZuGcpx5xekfpGCE8U130_assertion SIO_000772 25847929 NP1276270.RA6fshZS7muOi4P-MIthWlNkR1oIZuGcpx5xekfpGCE8U130_provenance.
- NP1276270.RA6fshZS7muOi4P-MIthWlNkR1oIZuGcpx5xekfpGCE8U130_assertion wasDerivedFrom befree-2016 NP1276270.RA6fshZS7muOi4P-MIthWlNkR1oIZuGcpx5xekfpGCE8U130_provenance.
- NP1276270.RA6fshZS7muOi4P-MIthWlNkR1oIZuGcpx5xekfpGCE8U130_assertion wasGeneratedBy ECO_0000203 NP1276270.RA6fshZS7muOi4P-MIthWlNkR1oIZuGcpx5xekfpGCE8U130_provenance.